rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers
The Journal of Infectious Diseases2005Vol. 191(5), pp. 710–718
Citations Over TimeTop 10% of 2005 papers
Anna P. Durbin, Stephen S. Whitehead, Julie H. McArthur, John R. Perreault, Joseph E. Blaney, Bhavin Thumar, Brian R. Murphy, Ruth A. Karron
Abstract
The rDEN4 Delta 30 vaccine is safe and induced an antibody response that was broadly neutralizing against genotypically diverse DEN-4 viruses. It is a promising vaccine candidate for inclusion in a tetravalent dengue vaccine formulation.
Related Papers
- → Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years(2012)91 cited
- → Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate(2011)53 cited
- → Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial(2020)29 cited
- → Dengue Virus Type 2 Vaccine: Reactogenicity and Immunogenicity in Soldiers(1984)75 cited
- → The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue(1997)40 cited